Indolent Lymphoma
Conference Coverage
Survival data reported from largest CAR T trial in B-cell lymphoma
ORLANDO – Progression-free survival results were best among complete responders and patients with primary mediastinal large B-cell lymphoma or...
Conference Coverage
5F9 plus rituximab take a bite out of drug-resistant NHL
AMSTERDAM – The combination thwarts a mechanism that non-Hodgkin lymphomas use to evade immune surveillance.
Conference Coverage
R2 appears active in high-risk FL and MZL
CHICAGO – R2 produced responses in patients who were refractory to rituximab or both lenalidomide and rituximab at baseline.
News
FDA approves lenalidomide/rituximab for previously treated FL, MZL
The approval is based on results from the phase 3 AUGMENT trial, which compared the combination treatment with placebo in previously treated...
From the Journals
In situ vaccination produced responses in indolent NHL
In situ vaccination induced regression of tumors that were directly targeted, as well as tumors that were not treated, in a small study of...
From the Journals
High survival in relapsed FL after primary radiotherapy
The study supports the role of primary radiotherapy in the treatment of early-stage follicular lymphoma. But researchers found that patients who...
From the Journals
BCL expression intensity key in distinguishing FL lesions
BCL2 expression intensity is the “single most valuable clue” in differentiating primary cutaneous follicular center-cell lymphoma from secondary...
Conference Coverage
GALLIUM: MRD response correlates with outcomes in follicular lymphoma
SAN DIEGO – MRD response at the end of induction correlates with outcomes in previously untreated follicular lymphoma patients receiving...
News
Umbralisib gains FDA breakthrough designation for MZL
Umbralisib is a PI3K-delta inhibitor being developed for the treatment of adults with marginal zone lymphoma.
From the Journals
Study supports need for less toxic therapies in FL
The study examines causes of death for follicular lymphoma patients in the rituximab era.
News
FDA approves rituximab biosimilar for lymphoma
Truxima is the first biosimilar approved in the United States to treat non-Hodgkin lymphoma.